Literature DB >> 3279767

Clinical spectrum of the upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Natural history, symptomatology, and significance.

J H Butt1, J S Barthel, R A Moore.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) relieve rheumatic pain and are in extensive use. Symptomatic complications of NSAIDs requiring the discontinuation of their use occur in 2 to 10 percent of patients with rheumatic diseases in sharp contrast to the common asymptomatic problems of gastroduodenal erosions, ulcerations, and bleeding, with resulting anemia in more than 40 percent of these patients. Opinions concerning the clinical significance of these complications are not uniform. The natural history of the effects of NSAIDs on the gastroduodenal mucosa reveals a sequence of initial subepithelial hemorrhage over a 24-hour period followed by gastroduodenal erosions and ulcerations in the next two weeks. From one week to three months, gastroduodenal erosions and ulcerations disappear in about half of the patients as an adaptation to continuing NSAID ingestion occurs. Hemorrhage may occur at any time in most patients and in a small minority (1 percent) it is massive. Non-aspirin NSAIDs (NANSAIDs) exhibit significantly fewer complications than do aspirin. These complications, however, demand considerable clinical attention and are ordered in a constant hierarchy, suggesting variable risks of complications among agents. NSAIDs are a blessing for those who have chronic pain, but that blessing does not prevent significant asymptomatic complications in the same patients. Prophylaxis for high-risk groups, such as women over the age of 65 years, should be subjected to study.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279767     DOI: 10.1016/0002-9343(88)90248-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

1.  Non-steroidal Anti-inflammatory Drugs: Monitoring to help prevent serious adverse effects.

Authors:  B Cardario; A A McKinnon
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

Review 2.  Adenosine and the adaptation to exercise.

Authors:  R E Simpson; J W Phillis
Journal:  Sports Med       Date:  1993-04       Impact factor: 11.136

Review 3.  Adenosine in exercise adaptation.

Authors:  R E Simpson; J W Phillis
Journal:  Br J Sports Med       Date:  1992-03       Impact factor: 13.800

4.  Cyclooxygenase inhibition with indomethacin increases human duodenal mucosal response to prostaglandin E1.

Authors:  D L Hogan; M A Ballesteros; M A Koss; J I Isenberg
Journal:  Dig Dis Sci       Date:  1989-12       Impact factor: 3.199

Review 5.  The problems and pitfalls of NSAID therapy in the elderly (Part II).

Authors:  A G Johnson; R O Day
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

6.  A comparison of two prostaglandin analogues (enprostil vs misoprostol) in the treatment of acute duodenal ulcer disease.

Authors:  C K Ching; S K Lam
Journal:  J Gastroenterol       Date:  1995-10       Impact factor: 7.527

7.  : a prospective, randomised, double-blind, controlled multicentre study.

Authors:  H Røgind; H Bliddal; D Klokker; F Jensen
Journal:  Clin Drug Investig       Date:  1997       Impact factor: 2.859

Review 8.  Treatment of peptic ulcer disease in the arthritic patient.

Authors:  D Nunes; N P Kennedy; D G Weir
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

9.  Early morbidity after total hip replacement: rheumatoid arthritis versus osteoarthritis.

Authors:  R H White; S A McCurdy; R A Marder
Journal:  J Gen Intern Med       Date:  1990 Jul-Aug       Impact factor: 5.128

Review 10.  Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity.

Authors:  L McEvoy; D F Carr; M Pirmohamed
Journal:  Front Pharmacol       Date:  2021-06-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.